Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: A pragmatic multicentre, prospective, randomized, controlled study.


Journal

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 25 02 2022
accepted: 02 05 2022
pubmed: 2 6 2022
medline: 6 8 2022
entrez: 1 6 2022
Statut: ppublish

Résumé

To establish whether a slow or a rapid withdrawal of antiepileptic monotherapy influences relapse rate in seizure-free adults with epilepsy and calculates compliance and differences in the severity of relapses, based on the occurrence of status epilepticus, seizure-related injuries, and death. This is a multicentre, prospective, randomized, open label, non-inferiority trial in people aged 16 + years who were seizure-free for more than 2 years. Patients were randomized to slow withdrawal (160 days) or rapid withdrawal (60 days) and were followed for 12 months. The primary outcome was the probability of a first seizure relapse within the 12-months follow-up. The secondary outcomes included the cumulative probability of relapse at 3, 6, 9, and 12 months. A non-inferiority analysis was performed with non-inferiority margin of - 0.15 for the difference between the probabilities of seizure recurrence in slow versus rapid withdrawal. The sample comprised 48 patients, 25 randomized to slow withdrawal and 23 to rapid withdrawal. Median follow-up was 11.9 months. In the intention-to-treat population, 3 patients in the slow-withdrawal group and 1 in the rapid withdrawal group experienced seizure relapses. The corresponding probabilities of seizure recurrence were 0.12 for slow withdrawal and 0.04 for rapid withdrawal, giving a difference of 0.08 (95% CI - 0.12; 0.27), which is entirely above the non-inferiority margin. No patients developed status epilepticus and seizure-related injuries or died. Risks were similar in the Per-Protocol population. Seizure-relapse rate after drug discontinuation is lower than in other reports, without complications and unrelated to the duration of tapering.

Identifiants

pubmed: 35648267
doi: 10.1007/s10072-022-06121-9
pii: 10.1007/s10072-022-06121-9
doi:

Substances chimiques

Anticonvulsants 0

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

5133-5141

Subventions

Organisme : Italian Health Ministry
ID : GR-2013-02358677

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2022. Fondazione Società Italiana di Neurologia.

Références

Beghi E, Giussani G, Sander JW (2015) The natural history and prognosis of epilepsy. Epileptic Disord 17(3):243–253. https://doi.org/10.1684/epd.2015.0751
doi: 10.1684/epd.2015.0751 pubmed: 26234761
Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342(5):314–319. https://doi.org/10.1056/NEJM200002033420503
doi: 10.1056/NEJM200002033420503 pubmed: 10660394
Berg AT, Shinnar S (1994) Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 44(4):601–608. https://doi.org/10.1212/wnl.44.4.601
doi: 10.1212/wnl.44.4.601 pubmed: 8164811
Specchio LM, Beghi E (2004) Should antiepileptic drugs be withdrawn in seizure-free patients? CNS Drugs 18(4):201–212. https://doi.org/10.2165/00023210-200418040-00001
doi: 10.2165/00023210-200418040-00001 pubmed: 15015901
Lossius MI, Hessen E, Mowinckel P et al (2008) Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia 49(3):455–463. https://doi.org/10.1111/j.1528-1167.2007.01323.x
doi: 10.1111/j.1528-1167.2007.01323.x pubmed: 17888074
Beghi E, Cornaggia C, RESt-1 Group (2002) Morbidity and accidents in patients with epilepsy: results of a European cohort study. Epilepsia 43(9):1076–1083. https://doi.org/10.1046/j.1528-1157.2002.18701.x
van den Broek M, Beghi E, RESt-1 Group (2004) Accidents in patients with epilepsy: types, circumstances, and complications: a European cohort study. Epilepsia 45(6):667–672. https://doi.org/10.1111/j.0013-9580.2004.33903.x
Beghi E, Giussani G, Grosso S et al (2013) Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy. Epilepsia 54(Suppl 7):2–12. https://doi.org/10.1111/epi.12305
doi: 10.1111/epi.12305 pubmed: 24099051
Duncan JS, Shorvon SD (1987) Rates of antiepileptic drug reduction in active epilepsy–current practice. Epilepsy Res 1(6):357–364. https://doi.org/10.1016/0920-1211(87)90060-x
doi: 10.1016/0920-1211(87)90060-x pubmed: 3504410
Emerson R, D’Souza BJ, Vining EP, Holden KR, Mellits ED, Freeman JM (1981) Stopping medication in children with epilepsy: predictors of outcome. N Engl J Med 304(19):1125–1129. https://doi.org/10.1056/NEJM198105073041902
doi: 10.1056/NEJM198105073041902 pubmed: 7219445
Callaghan N, Garrett A, Goggin T(1988) Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study [published correction appears in N Engl J Med 1988 Jul 21;319(3):188]. N Engl J Med 318(15):942–946. https://doi.org/10.1056/NEJM198804143181502
Mastropaolo C, Tondi M, Carboni F, Manca S, Zoroddu F (1992) Prognosis after therapy discontinuation in children with epilepsy. Eur Neurol 32(3):141–145. https://doi.org/10.1159/000116811
doi: 10.1159/000116811 pubmed: 1592070
Ranganathan LN, Ramaratnam S (2006) Rapid versus slow withdrawal of antiepileptic drugs. Cochrane Database Syst Rev (2):CD005003. Published 2006 Apr 19. https://doi.org/10.1002/14651858.CD005003.pub2
Tennison M, Greenwood R, Lewis D, Thorn M (1994) Discontinuing antiepileptic drugs in children with epilepsy. A comparison of a six-week and a nine-month taper period. N Engl J Med 330(20):1407–1410.   https://doi.org/10.1056/NEJM199405193302002
Gasparini S, Ferlazzo E, Giussani G et al (2016) Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study. Neurol Sci 37(4):579–583. https://doi.org/10.1007/s10072-016-2483-3
doi: 10.1007/s10072-016-2483-3 pubmed: 26809952
Proposal for revised classification of epilepsies and epileptic syndromes (1989) Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30(4):389–399. https://doi.org/10.1111/j.1528-1157.1989.tb05316.x
Farrington CP, Manning G (1990) Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 9(12):1447–1454. https://doi.org/10.1002/sim.4780091208
doi: 10.1002/sim.4780091208 pubmed: 2281232
Beghi E, Beretta S, Colombo M et al (2021) Discontinuation of antiseizure medications in seizure-free patients with long-term follow-up: Patients’ profile, seizure recurrence, and risk factors. Epilepsy Behav 117:107871. https://doi.org/10.1016/j.yebeh.2021.107871
doi: 10.1016/j.yebeh.2021.107871 pubmed: 33690066

Auteurs

Edoardo Ferlazzo (E)

Department of Medical and Surgical Sciences, "Magna Græcia" University of Catanzaro, Catanzaro, Italy.
Regional Epilepsy Centre, Great Metropolitan Hospital, Via Melacrino, 89100, Reggio Calabria, Italy.

Giorgia Giussani (G)

Laboratory of Neurological Disorders, Department of Neuroscience, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Sara Gasparini (S)

Department of Medical and Surgical Sciences, "Magna Græcia" University of Catanzaro, Catanzaro, Italy.
Regional Epilepsy Centre, Great Metropolitan Hospital, Via Melacrino, 89100, Reggio Calabria, Italy.

Elisa Bianchi (E)

Laboratory of Neurological Disorders, Department of Neuroscience, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Vittoria Cianci (V)

Regional Epilepsy Centre, Great Metropolitan Hospital, Via Melacrino, 89100, Reggio Calabria, Italy.

Vincenzo Belcastro (V)

Neurology Unit, Maggiore Hospital, ASST Lodi, Lodi, Italy.

Roberto Cantello (R)

Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Azienda Ospedaliero-Universitaria "Maggiore Della Carità", Novara, Italy.

Gionata Strigaro (G)

Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Azienda Ospedaliero-Universitaria "Maggiore Della Carità", Novara, Italy.

Matilde Lazzari (M)

Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Azienda Ospedaliero-Universitaria "Maggiore Della Carità", Novara, Italy.

Amedeo Bianchi (A)

Department of Neurology and Epilepsy Centre, San Donato Hospital, Arezzo, Italy.

Martina Guadagni (M)

Department of Neurology and Epilepsy Centre, San Donato Hospital, Arezzo, Italy.

Silvia Pradella (S)

Department of Neurology and Epilepsy Centre, San Donato Hospital, Arezzo, Italy.

Angela La Neve (A)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

Teresa Francavilla (T)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

Nicola Pilolli (N)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

Paola Banfi (P)

Department of Emergency, Medicine Epilepsy Center, Neurology Unit, Circolo Hospital, Varese, Italy.

Francesco Turco (F)

Department of Emergency, Medicine Epilepsy Center, Neurology Unit, Circolo Hospital, Varese, Italy.

Marta Piccioli (M)

UOC Neurology, PO San Filippo Neri, ASL Roma 1, Rome, Italy.

Luigi Polidori (L)

UOC Neurology, PO San Filippo Neri, ASL Roma 1, Rome, Italy.

Teresa Anna Cantisani (T)

Neurophysiopathology, Perugia Hospital, Perugia, Italy.

Rossella Papetti (R)

Neurophysiopathology, Perugia Hospital, Perugia, Italy.

Michela Cecconi (M)

Neurophysiopathology, Perugia Hospital, Perugia, Italy.

Elisabetta Pupillo (E)

Laboratory of Neurological Disorders, Department of Neuroscience, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Emilio Davide Arippol (E)

Laboratory of Neurological Disorders, Department of Neuroscience, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Gabriele Enia (G)

Laboratory of Neurological Disorders, Department of Neuroscience, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Sabrina Neri (S)

Department of Medical and Surgical Sciences, "Magna Græcia" University of Catanzaro, Catanzaro, Italy.
Regional Epilepsy Centre, Great Metropolitan Hospital, Via Melacrino, 89100, Reggio Calabria, Italy.

Umberto Aguglia (U)

Department of Medical and Surgical Sciences, "Magna Græcia" University of Catanzaro, Catanzaro, Italy. aguglia@unicz.it.
Regional Epilepsy Centre, Great Metropolitan Hospital, Via Melacrino, 89100, Reggio Calabria, Italy. aguglia@unicz.it.

Ettore Beghi (E)

Laboratory of Neurological Disorders, Department of Neuroscience, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH